Loomis, Sayles & Company’s Exelixis EXEL Stock Holding History

Loomis, Sayles & Company’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-8,450	Closed	-$176K	–	979
2022 Q2	$176K	Buy	+8,450	New	+$174K	﹤0.01%	511

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company's EXEL Position: Q3 2022 in Review

Loomis, Sayles & Company sold out of Exelixis (EXEL) in Q3 2022, closing a stake of 8,450 shares — an estimated $176K sold.

Loomis, Sayles & Company first reported a position in EXEL in Q2 2022 and held it in 1 quarter. The position peaked at $176K in Q2 2022. 400 funds tracked by Wall St. Rank hold EXEL as of Q3 2022.

Loomis, Sayles & Company reported no remaining Exelixis position as of Q3 2022 after selling out during the quarter.
Loomis, Sayles & Company sold 8,450 Exelixis shares in Q3 2022, an estimated $176K.
Loomis, Sayles & Company first reported a position in Exelixis in Q2 2022 and held it in 1 quarter.
Loomis, Sayles & Company's Exelixis position peaked at $176K in Q2 2022.
400 funds tracked by Wall St. Rank held Exelixis as of Q3 2022.

Based on Loomis, Sayles & Company's 13F filing for Q3 2022, filed 14 Nov 2022.